Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

Home > Science Hub > Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
Back to the list

March 3, 2026

Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2

You might also be interested by

Posters

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

March 3, 2026

More info

Posters

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

More info

Web News

CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI

March 3, 2026

More info

News

Slope and CellCarta Expand Collaboration with Lab Kit Inventory Portal Agreement

February 3, 2026

More info